热门资讯> 正文
Cogent bBosiences获得高达4亿美元的非稀释性融资
2025-06-11 20:11
- Cogent Biosciences (NASDAQ:COGT) announced on Wednesday it has secured a debt financing facility of up to $400 million with credit funds managed by SLR Capital Partners.
- Under the terms of the agreement, Cogent drew $50 million from the facility at closing. An additional $100 million is available during 2025 at Cogent’s discretion, subject to successful top-line data readouts from SUMMIT and PEAK bezuclastinib pivotal trials.
- "An additional $50 million is available upon achievement of early commercial success following bezuclastinib launch. The remaining $200 million is available at mutual agreement of Cogent and SLR," said the company.
- Cogent said it remains on track in July to announce top-line results from SUMMIT, a registration-directed, randomized, double-blind, placebo-controlled, global, multicenter, clinical trial of bezuclastinib in patients with NonAdvSM.
- COGT +0.40% premarket to $7.45.
- Source: Press Release
More on Cogent Biosciences
- Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement
- Seeking Alpha’s Quant Rating on Cogent Biosciences
- Historical earnings data for Cogent Biosciences
- Financial information for Cogent Biosciences
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
